Hangzhou Eli Radiopharma Co., Ltd. (“Eli Radiopharma“) announced the completion of a Series A financing round raising nearly RMB 400 million, capital that will be primarily deployed to advance the company’s core innovative pipeline toward the clinical stage and build out its precision radiotheranostic platform for oncology and neuroscience diseases.
Financing Snapshot
| Item | Detail |
|---|---|
| Company | Hangzhou Eli Radiopharma Co., Ltd. |
| Round | Series A |
| Amount Raised | Nearly RMB 400 million |
| Announcement Date | 12 November 2026 |
| Primary Use of Proceeds | Advance core innovative pipeline to the clinical stage |
| Specific Allocations | Preclinical research, Investigational New Drug (IND) filings, and early‑stage clinical development |
| Secondary Allocations | R&D platform construction, talent acquisition, clinical development capability, and global expansion |
| Investors / Valuation | Not disclosed |
Company Profile
- Founded: 2024, headquartered in Hangzhou, China.
- Business Focus: A biopharmaceutical company dedicated to developing innovative radiopharmaceuticals and high‑tech applications.
- Core Strategy: Create precision radiotheranostic solutions – integrated diagnostic and therapeutic modalities that use matched radiolabeled agents to image disease and then deliver targeted radiation therapy to the same molecular target.
- Target Diseases: A variety of oncology and neuroscience indications.
- Pipeline Detail: Specific drug candidates, targets, radioisotopes, or lead programs were not disclosed in the announcement.
Use of Proceeds & Strategic Priorities
- Clinical‑Stage Push: The bulk of funding supports the transition from preclinical programs to the clinic, covering preclinical research, IND filings, and early‑stage clinical development of drug candidates.
- Platform Construction: Proceeds will further strengthen R&D platform buildout – infrastructure critical in radiopharma, where isotope supply, radiochemistry, GMP manufacturing, and radiation‑safety capabilities determine development velocity.
- Talent Acquisition: Hiring is explicitly named as a funding priority, reflecting the scarce, specialized skill set required at the intersection of radiochemistry, nuclear medicine, and clinical development.
- Global Ambitions: The round will continuously enhance clinical development and global expansion capabilities, signaling intent to build a pipeline competitive beyond the Chinese market.
- Long‑Term Backing: The company framed the financing as robust support for the sustained advancement and long‑term growth of its innovative radiopharmaceutical pipeline.
Market Impact & Outlook
- Sector Tailwinds: Radiopharmaceuticals have become one of the hottest areas in oncology drug development, propelled by the commercial success of targeted radioligand therapies from major pharmas and a wave of licensing deals; Chinese radiotheranostic startups are attracting growing investor attention as the model matures.
- Radiotheranostic Appeal: The integrated diagnostic‑therapeutic (“see it, treat it”) approach enables patient selection by imaging before therapy – a precision‑medicine logic that resonates with both regulators and payers.
- Financing Signal: Raising nearly RMB 400 million in a Series A within roughly two years of founding (2024) indicates strong investor conviction in the team and platform; investor identities and valuation were not disclosed.
- Execution Milestones Ahead: Key catalysts include completion of preclinical packages, first IND filings, initiation of early‑stage clinical trials, and progress on global expansion – timelines for which were not disclosed.
- China Radiopharma Landscape: The round adds to a deepening cluster of Chinese nuclear‑medicine ventures, where isotope supply chain development and hospital radiopharmacy infrastructure remain the sector’s critical bottlenecks and opportunities.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Eli Radiopharma’s use of Series A proceeds, pipeline advancement, IND filings, clinical development, and global expansion plans. Actual results may differ materially due to risks including preclinical and clinical outcomes, regulatory review timelines, radioisotope supply constraints, competitive dynamics, and capital market conditions. Investor identities, valuation, pipeline specifics, and milestone timelines have not been disclosed.-Fineline Info & Tech
